Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Resolving the mystery of preeclampsia

21.10.2016

Preeclampsia (PE) is a potentially life-threatening disorder during pregnancy, putting the mother and the new born at an increased risk for disease and death. PE is frequent, affecting 3-5% of pregnancies worldwide, making it the leading cause of maternal and fetal morbidity and mortality. The causes and mechanisms involved in the origin and progression of PE remain unresolved and medical therapies are accordingly lacking.

The delivery of placenta remains the only effective remedy resulting in pre-term delivery, which in itself constitutes an increased risk for the newborn. A group of researchers lead by the team of Prof. Berend Isermann, Otto-von-Guericke University, Magdeburg, now unraveled a key step in the manifestation of PE, which improves our understanding of PE. These results are expected to lead to new therapeutic approaches to defeat PE. The findings of this study has been recently published by the journal “Blood”.


Activated platelets in the placenta after extracellular vesicle injections

Autor: Shrey Kohli

PE has its origin within the placenta, but affects multiple organ systems causing hypertension (> 140/90 mmHg), renal dysfunction (proteinuria, glomerular endotheliosis), elevated liver enzymes, and a hypercoaguble vascular system. The events can be catastrophic, leading to a frequently lethal condition known as HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome.

Platelets are key regulators of blood coagulation system and enhanced platelet activation has been associated with PE. Also, women with PE have been shown to have higher count of extracellular vesicles (EV), cell-fragments shed from inflamed cells. The association of EV and platelet activation with PE is known, but how this may contribute to the disease and whether this can be therapeutically target remained unknown hitherto.

Berend Isermann, Shrey Kohli and colleagues identified in their work a new function of platelets and EVs in PE. Platelets and EVs cause a thrombo-inflammatory disorder at the feto-maternal interface. Procoagulant EVs activate platelets, which accumulate particularly within the placental vascular bed. There the platelets release ATP and thus cause inflammasome activation in the embryonic trophoblast.

This leads to fetal death, intra-uterine growth restriction, renal failure, and maternal hypertension – all hallmarks of PE in humans. The investigators corroborated the relevance of these findings for human patients with PE in close cooperation with the gynecology departments at the university in Magdeburg and Erlangen and the local city hospital in Magdeburg. Importantly, anti-platelet agents such as Aspirin or pharmaceutics targeting the inflammasome pathway such as Anakinra, Apyrase or purinergic receptor antagonists inhibit the thrombo-inflammatory response within the placenta and prevent the manifestation of PE.

Thus, these results, which were published in Blood, the leading journal for hemostasis and blood-cell related diseases, identify a new mechanism causing PE and suggest new therapeutic targets allowing to target PE.

Blood 2016 :blood-2016-03-705434; doi:10.1182/blood-2016-03-705434

http://www.bloodjournal.org/content/early/2016/09/02/blood-2016-03-705434.long?s...

Legend: Double immunofluorescence staining showing activated platelets (CD62P, P-selectin; red) in the placenta (left), but not in the kidney (right), after injections of mouse endothelial cell derived EV. CD62P (red) co-localizes (yellow) with GP1bα (green) indicating presence of activated platelets within the placenta (Placenta, upper left panel). Co-localization (yellow) of activated platelets (CD62P; red) and Gcm-1 positive syncytiotrophoblast (arrows, green) indicates direct contact of activated platelets with syncytiotrophoblasts, which line maternal blood spaces within the placenta; (Placenta, lower left panel); arrow heads: autofluorescence of erythrocytes.

Contact: Prof. Dr. Berend Isermann and Shrey Kohli
Shrey Kohli (AG Isermann)
Institute for Clinical Chemistry and Pathobiochemistry
Otto-von-Guericke Univeristy (Medical Faculty)
Leipziger Str. 44, 39120 Magdeburg
Germany
Tel.: +49 391 67-13921
E-Mail: berend.isermann@med.ovgu.de und shrey.kohli@med.ovgu.de

Kornelia Suske | idw - Informationsdienst Wissenschaft
Further information:
http://www.med.uni-magdeburg.de/

More articles from Health and Medicine:

nachricht The cytoskeleton of neurons has been found to be involved in Alzheimer's disease
18.01.2019 | University of the Basque Country

nachricht Bioinspired nanoscale drug delivery method developed by WSU, PNNL researchers
10.01.2019 | Washington State University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ten-year anniversary of the Neumayer Station III

The scientific and political community alike stress the importance of German Antarctic research

Joint Press Release from the BMBF and AWI

The Antarctic is a frigid continent south of the Antarctic Circle, where researchers are the only inhabitants. Despite the hostile conditions, here the Alfred...

Im Focus: Ultra ultrasound to transform new tech

World first experiments on sensor that may revolutionise everything from medical devices to unmanned vehicles

The new sensor - capable of detecting vibrations of living cells - may revolutionise everything from medical devices to unmanned vehicles.

Im Focus: Flying Optical Cats for Quantum Communication

Dead and alive at the same time? Researchers at the Max Planck Institute of Quantum Optics have implemented Erwin Schrödinger’s paradoxical gedanken experiment employing an entangled atom-light state.

In 1935 Erwin Schrödinger formulated a thought experiment designed to capture the paradoxical nature of quantum physics. The crucial element of this gedanken...

Im Focus: Nanocellulose for novel implants: Ears from the 3D-printer

Cellulose obtained from wood has amazing material properties. Empa researchers are now equipping the biodegradable material with additional functionalities to produce implants for cartilage diseases using 3D printing.

It all starts with an ear. Empa researcher Michael Hausmann removes the object shaped like a human ear from the 3D printer and explains:

Im Focus: Elucidating the Atomic Mechanism of Superlubricity

The phenomenon of so-called superlubricity is known, but so far the explanation at the atomic level has been missing: for example, how does extremely low friction occur in bearings? Researchers from the Fraunhofer Institutes IWM and IWS jointly deciphered a universal mechanism of superlubricity for certain diamond-like carbon layers in combination with organic lubricants. Based on this knowledge, it is now possible to formulate design rules for supra lubricating layer-lubricant combinations. The results are presented in an article in Nature Communications, volume 10.

One of the most important prerequisites for sustainable and environmentally friendly mobility is minimizing friction. Research and industry have been dedicated...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Our digital society in 2040

16.01.2019 | Event News

11th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Aachen, 3-4 April 2019

14.01.2019 | Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

 
Latest News

Additive manufacturing reflects fundamental metallurgical principles to create materials

18.01.2019 | Materials Sciences

How molecules teeter in a laser field

18.01.2019 | Life Sciences

The cytoskeleton of neurons has been found to be involved in Alzheimer's disease

18.01.2019 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>